Leap Therapeutics Management
Management criteria checks 3/4
Leap Therapeutics' CEO is Doug Onsi, appointed in Jan 2011, has a tenure of 13.83 years. total yearly compensation is $1.53M, comprised of 43.6% salary and 56.4% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth €207.40K. The average tenure of the management team and the board of directors is 4.6 years and 7.8 years respectively.
Key information
Doug Onsi
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 43.6% |
| CEO tenure | 13.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 4.6yrs |
| Board average tenure | 7.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$65m |
| Jun 30 2024 | n/a | n/a | -US$60m |
| Mar 31 2024 | n/a | n/a | -US$53m |
| Dec 31 2023 | US$2m | US$669k | -US$81m |
| Sep 30 2023 | n/a | n/a | -US$81m |
| Jun 30 2023 | n/a | n/a | -US$82m |
| Mar 31 2023 | n/a | n/a | -US$86m |
| Dec 31 2022 | US$2m | US$637k | -US$55m |
| Sep 30 2022 | n/a | n/a | -US$53m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$42m |
| Dec 31 2021 | US$2m | US$596k | -US$41m |
| Sep 30 2021 | n/a | n/a | -US$37m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$29m |
| Dec 31 2020 | US$2m | US$513k | -US$38m |
| Sep 30 2020 | n/a | n/a | -US$39m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$817k | US$400k | -US$33m |
| Sep 30 2019 | n/a | n/a | -US$24m |
| Jun 30 2019 | n/a | n/a | -US$22m |
| Mar 31 2019 | n/a | n/a | -US$21m |
| Dec 31 2018 | US$682k | US$400k | -US$23m |
| Sep 30 2018 | n/a | n/a | -US$31m |
| Jun 30 2018 | n/a | n/a | -US$31m |
| Mar 31 2018 | n/a | n/a | -US$31m |
| Dec 31 2017 | US$3m | US$397k | -US$30m |
Compensation vs Market: Doug's total compensation ($USD1.53M) is above average for companies of similar size in the German market ($USD475.63K).
Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.
CEO
Doug Onsi (55 yo)
13.8yrs
Tenure
US$1,534,507
Compensation
Mr. Douglas E. Onsi, also known as Doug, J.D., serves as Director at Leap Therapeutics, Inc. since March 18, 2020. He serves as Managing Director of HCV Management VIII, LLC (formerly known as HealthCare V...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO, General Counsel | 13.8yrs | US$1.53m | 0.19% € 207.4k | |
| Chief Operating Officer | 8.8yrs | US$1.00m | 0.013% € 14.3k | |
| Chief Medical Officer | 4.6yrs | US$999.40k | 0.013% € 14.1k | |
| Chief Scientific Officer | 1.6yrs | no data | no data | |
| Chief Manufacturing Officer | 4.6yrs | no data | 0.013% € 14.1k | |
| VP and Head of Regulatory Affairs & Quality | 4.3yrs | no data | no data |
4.6yrs
Average Tenure
54.5yo
Average Age
Experienced Management: 5MC's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO, General Counsel | 4.7yrs | US$1.53m | 0.19% € 207.4k | |
| Chairman | 13.8yrs | US$744.18k | 0.013% € 14.3k | |
| Independent Director | 8.8yrs | US$126.62k | 0.68% € 738.0k | |
| Lead Independent Director | 8.8yrs | US$188.86k | 0% € 0 | |
| Independent Director | 7.8yrs | US$118.24k | 0% € 0 | |
| Independent Director | 8.8yrs | US$112.12k | 0% € 0 | |
| Independent Director | 7.8yrs | US$121.62k | 0% € 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.2yrs | US$112.12k | 0% € 0 | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data |
7.8yrs
Average Tenure
70yo
Average Age
Experienced Board: 5MC's board of directors are considered experienced (7.8 years average tenure).